Medical Exoskeleton Market to Reach USD 233.71 Million by 2034, Growing at a 9.88% CAGR

The medical exoskeleton market was valued at approximately USD 100.18 million in 2025 and is estimated at USD 109.99 million in 2026, according to Polaris Market Research. It is projected to reach USD 233.71 million by 2034, growing at a CAGR of 9.88% during the 2026–2034 forecast period. Medical exoskeletons are wearable robotic or orthotic devices worn over the legs, hips or arms that support, restore or train motor function in people with spinal cord injury, stroke, multiple sclerosis, cerebral palsy and other neurological and musculoskeletal conditions. Rising spinal cord injury prevalence, a larger geriatric population and technological advancement are driving the market forward.

Medical Exoskeleton Market Growth and Industry Outlook

Growing global demand for rehabilitation services is a central growth factor. High rates of injury and disease create a need for long-term patient care and post-surgery rehabilitation, and medical exoskeletons help patients regain motor skills and mobility. For clinicians, the devices offer an effective tool for gait training, can reduce therapists’ workload and give patients a greater range of motion during therapy. This has encouraged wider use in hospitals, rehabilitation centers and clinics.

The ageing population adds further momentum. According to Eurostat, 450.6 million people in Europe, or 22.0% of the population, are aged 65 years and above. Older adults face a higher prevalence of chronic conditions such as Parkinson’s disease, along with muscle weakness and reduced balance that raise the risk of falls. Exoskeletons can provide physical assistance and help older patients regain motor function after an accident or surgery.

Key Market Drivers and Emerging Trends

Polaris Market Research identifies three principal drivers: the rising prevalence of spinal cord injury and stroke, growing reimbursement for personal-use products and increasing clinical adoption. Insurance and health-related reimbursement programs can widen access to costly devices, although coverage varies by country, device type and indication. In the U.S., personal exoskeletons are growing in popularity as reimbursement policies and self-balancing technologies, which remove the need for crutches, continue to develop.

Artificial intelligence is also shaping product development. AI-enabled systems can detect patient movements, adjust assistance to individual needs and help therapists monitor progress and personalize programs. Other emerging trends include gait analytics, bioelectrical control, hybrid FES-exoskeleton therapy, sensor fusion and connected rehabilitation ecosystems that link clinicians, cloud analytics and remote monitoring.

Adoption barriers remain. High device cost, variation in payer coverage, patient suitability, a shortage of skilled professionals, device weight and comfort, battery limitations and device fit are cited as restraints, particularly for small-scale rehabilitation facilities. Opportunities include the rising need for home-based care, growing demand for upper-limb devices and the expansion of rehabilitation centers in APAC and GCC countries.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/medical-exoskeleton-market

Segment and Application Insights

By component, hardware accounted for the largest share at 68.4% in 2025, supported by demand for motors, sensors, frames and control systems, while software is expected to grow fastest at a CAGR of 12.1%. By type, the powered segment held the highest share at 81.6% in 2025. Powered exoskeletons use batteries and motors to assist sitting, standing and rehabilitation activities, whereas the passive segment, which relies on springs and joints, is anticipated to expand at a CAGR of 8.9%.

Rigid structures led the structure category with a 58.6% share, and the lower-limb exoskeleton segment accounted for the largest extremity share at 62.4%, reflecting demand for devices that support hip, knee and leg movement. The upper-limb category is expected to grow at a CAGR of 10.2%, supported by rising stroke incidence.

Spinal cord injury was the largest application with a 39.8% share, while stroke is expected to grow at a CAGR of 11.3%, followed by multiple sclerosis at 10.6% and cerebral palsy at 9.8%. By end use, hospitals and specialty clinics held 52.7% in 2025, with rehabilitation centres expected to grow at 10.8%, physiotherapy centres at 10.4% and home and community settings at 12.2%. The market is bifurcated into rehabilitation exoskeletons, which clinics and physiotherapy centers procure for physical therapy-assisted gait training, and personal exoskeletons, which individuals buy for home use on physician prescription.

Regional Market Perspective

North America was the largest market in 2025 with a share of 46.21%, supported by advanced healthcare facilities and extensive rehabilitation services. The U.S. has a number of R&D initiatives and medical device manufacturers and is seeing a heightened incidence of cerebrovascular accidents and spinal cord injury, while Canada’s market is driven by growing emphasis on rehabilitation services. Europe is expected to grow at a CAGR of 9.4%, driven by its ageing population and well-developed healthcare services. Asia Pacific is anticipated to expand at 11.2%, helped by Japan’s ageing population, China’s focus on medical device manufacturing and Malaysia’s emphasis on rehabilitation services. Latin America is expected to grow at 9.6% and the Middle East and Africa at 10.1%, with Saudi Arabia and the UAE emphasizing specialized healthcare infrastructure.

Competitive Landscape

The market is competitive, with established medical technology companies and specialized robotics manufacturers focused on product development and clinical adoption. Key players include Lifeward Ltd., Ekso Bionics Holdings, CYBERDYNE, Wandercraft and Ottobock, while Myomo, Fourier Intelligence, B-Temia and Hocoma serve different rehabilitation and mobility needs. Companies compete through technological improvements, product comfort, clinical partnerships and geographic expansion.

Recent developments reflect this focus. In July 2026, Onyx Healthcare, Intel and FREE Bionics launched FREE Walk, an AI-powered lower-limb rehabilitation exoskeleton that processes EMG, pressure and inertial-sensor data for real-time gait assistance. In February 2026, Lifeward announced an agreement to acquire Skelable’s AI-enabled powered upper-body exoskeleton technology, intended to assist weakened or paralyzed arms and hands, primarily after stroke. In December 2025, Verita Neuro partnered with Lifeward to introduce the ReWalk Personal Robotic Exoskeleton into spinal cord injury rehabilitation programs in Thailand, Mexico and the UAE.

Regulation also shapes the field. In the United States, powered exoskeletons for the lower extremity are regulated as Class II prescription devices, and manufacturers generally must obtain 510(k) clearance, although FDA clearance does not establish payer coverage or reimbursement.

Future Market Outlook

The medical exoskeleton market is expected to keep growing as demand for rehabilitation and mobility support increases. Technological advancements may improve device comfort, affordability and ease of use, while growing healthcare investment and rising stroke and spinal cord injury cases are expected to create new opportunities. Continued demand for the lower-limb exoskeleton segment, wider clinical adoption of rehabilitation exoskeletons, home use and expanding healthcare infrastructure are all expected to support growth toward the USD 233.71 million forecast for 2034.

More Trending Latest Reports By Polaris Market Research:

Copper Clad Laminates Market

Antimicrobial Packaging Market

Abdominal Pads Market

Air Deflector Market

Antimicrobial Packaging Market

Case Packing Machine Market

Medical Specimen Tracking System Market

Automotive E-Compressor Market

Benign Prostatic Hyperplasia Surgical Treatment Market